

# KABRADRUGSLIMITED

### CIN-L02423MP1989PLC005438

Date: 14th August, 2018

To, The Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 (MH)

Ref: Scrip Code 524322

Sub: Outcome of Board Meeting 6/2018

#### Dear Sir/Madam,

With reference to the subject this is to inform you that the meeting of Board of Directors of Kabra Drugs Limited has held today i.e. August 14, 2018 at the Registered Office of the Company that commenced at 03.00 P.M. and concluded at 04.00 P.M. interalia, has taken the following decisions:

- 1. The Board has approved Standalone Unaudited Financial Results for the quarter ended June 30, 2018.
- The Board has taken on note Report on Reconciliation of Share Capital Audit under SEBI- DP Regulation 55 A, Shareholding pattern under Regulation 31 and Statement of Investors Complaint under Regulation 13(3) (LODR Regulations, 2015) for the quarter ended 30<sup>th</sup> June, 2018.

Kindly take the same on your records.

Thanking you,

Yours faithfully, FOR, KABRA DE

MANAGING DIN: 00760020



## KABRADRUGSLIMITED

### CIN-L02423MP1989PLC005438

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2018 (Rs In Lacs)  Year ended Year ended Year ended						
	PARTICULARS		Quarter ended 30.06.2018 31.03.2018		30.06.2017 31.03.2018	
	TAKTIOUMIU	30.06.2018				
(Refer Notes Below)		Unaudited	Audited	Unaudited 84.41	Audited 200.70	
	Revenue from Operations	-		84.41		
ı	Other Income	-	0.97		201.92	
III	Total Income (I+II)		0.97	84.41	201.92	
IV	EXPENSES				1	
	Cost of materials consumed		1.24	52.22	124.69	
	Purchases of Stock-in-Trade	-	-			
		1			1	
	Changes in inventories of finished goods, work-in-progress and stock in trade	-	- 1	(3.20)		
	Employee Benefits Expense	- 1	32.68	9.61	117.68	
	Finance Costs	-	15.21	•	25.19	
	Depreciation and Amortisation Expense	- 1	0.77	6.08	13.72	
	Other Expenses		11.08	19.18		
	Total Expenses		60.98	83.89	342.94	
v	Profit/(loss) before exceptional items and tax (III-IV)	-	(60.01)	0.52	(141.0)	
vi	Exceptional Items	-	(94.64)		(94.6	
VII	Profit/(loss) before tax (V-VI)	-	(154.65)	0.52	. (235.60	
VIII	Tax expense				1	
	Current Tax	-	•		·  ·	
	Deferred Tax		•		٠ ا	
	Tax for earlier years		•			
IX	Profit/(loss) for the period (VII-VIII)	·	(154.65)	0.52	(235.6	
X	Other comprehensive income				1	
	a Items that will not be reclassified to profit or loss					
	Fair value change in equity shares - OCI	-	- '		-	
	Remeasurement of defined benefit plan	- '	-		- [	
		+	(154.65)	0.52	(235.6	
XI	Total comprehensive income for the period		(134.03)	0.52		
хu	Paid up - Equity Share Capital	438.86	438.86	438.86	438.8	
	(Face value of Rs.10/- per share)				1 .	
	Trace value of 155.207 por single)			ļ	1	
XIII	Earnings per equity share (of Rs.10 each)					
	a Basic	-	(3.54)			
	b Diluted	-	(3.54)	0.01	(5.3	

#### Notes:

2 The Auditors of the Company have carried out a Limited Review of the result for the quarter ended 30th June 2018.

4 The figures for the corresponding previous quarter have been restated/regrouped wherever necessary, to make them comparable.

For Kabra Drugs Ltd.,

Place: Indore Date: 14.08.2018

Director. Shyam Kabra Managing Director Din: 00760020

<sup>1</sup> The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14th August 2018.

<sup>3</sup> The standalone unaudited financial results of the company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by SEBI